Cancer therapy sensitizer
US8071294B2 · kind B2 · utility
0Cited by
10References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 25, 2009 |
| Grant date | Dec 6, 2011 |
| Priority date | — |
| Expiry date | Nov 25, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K48/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compositions and methods for sensitizing cancer therapy. The invention provides such compositions comprising a SPARC family polypeptide or polynucleotide, as well as recombinant cells containing a SPARC family polypeptide or polynucleotide. The compositions and methods of the invention are useful in in vitro study of cancer therapy resistance, as well as ex vivo and in vivo therapy of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.